Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate
Authors:
- 1 May 1994
- journal article
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 67 (797) , 469-471
Abstract
Serum prostate specific antigen (PSA) has been suggested as an accurate means of monitoring prostate cancer. An analysis of PSA levels and bone scan findings was carried out in a heterogeneous group of patients with a view to determine whether PSA can accurately predict bone metastases in carcinoma prostate. Of the 48 patients studied, all 10 untreated cases had elevated PSA levels, eight having bone metastases. In 29 cases on follow-up after treatment of the primary, 10 out of 11 cases with normal PSA had a negative bone scan. In the nine who received hormonal therapy, the PSA levels were generally lower than others in the study group. Two out of four with normal PSA had bone metastases. In 26 cases with positive bone scans, 23 had elevated PSA levels (mean 109.9 ng ml-1). Among 22 patients who had normal bone scans, all 10 with high PSA were found to have soft tissue disease which could explain the elevated PSA. In those with normal PSA, 12 out of 15 patients had negative scans. PSA has fairly high sensitivity (86.5%) and negative predictive value (80%). But it suffers from low specificity (54.5%) and low positive predictive value (69.7%) for bone metastases. In an untreated patient with elevated PSA, a bone scan may be required to exclude bone metastases, whereas during follow-up after treatment, a normal PSA level may obviate a "routine" bone scan.Keywords
This publication has 8 references indexed in Scilit:
- Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer?British Journal of Radiology, 1992
- Prostate Specific Antigen in Hormonally Treated Stage D2 Prostate Cancer: Is it always an Accurate Indicator of Disease Status?Journal of Urology, 1991
- Predicting Radionuclide Bone Scan Findings in Patients with Newly Diagnosed, Untreated Prostate Cancer: Prostate Specific Antigen is Superior to All Other Clinical ParametersJournal of Urology, 1991
- Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. II. Radical Prostatectomy Treated PatientsJournal of Urology, 1989
- The Value of Serum Prostate Specific Antigen Determinations Before and after Radical ProstatectomyJournal of Urology, 1989
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987
- Tumour Markers in Prostatic Carcinoma. A Comparison of Prostate‐specific Antigen with Acid PhosphataseBritish Journal of Urology, 1987
- The National Survey of Prostate Cancer in the United States by the American College of SurgeonsJournal of Urology, 1982